Advertisement

Autoimmunity Highlights

, 9:2 | Cite as

Platelet-activating factor acetylhydrolase in primary antiphospholipid syndrome

  • Paul R. J. AmesEmail author
  • Luis L. Lopez
  • Mira Merashli
  • Eiji Matsuura
Open Access
Letter to the Editor

Dear Sir,

The interesting article by Fabris et al. shows that individuals screened for antiphospholipid antibodies (aPL) because of a thrombotic or obstetric history exhibit higher platelet-activating factor acetylhydrolase (PAF-AH) in plasma than control blood donors (p < 0.0001); amongst the aPL-positive participants, those lupus anticoagulant positive had higher PAF-AH than LA-negative patients (p = 0.03) and those positive for IgG anti-beta2 glycoprotein-I antibodies (aβ2GPI) presented with higher PAF-AH than patients positive for isolated IgM aβ2GPI (p = 0.03) [1].

To expand on this topic, we measured PAF-AH in 27 consecutive thrombotic primary antiphospholipid syndrome (PAPS) patients, in 17 thrombotic patients with inherited thrombophilia (IT) and in 23 healthy controls had given written consent for their plasma samples to be stored for research purposes (Table 1). In all participants, we measured IgG anticardiolipin (Cambridge Life Sciences, UK), IgG aβ2GPI (Corgenix, Denver, USA), β2GPI-oxidised low-density lipoprotein (β2GPI-oxLDL) complex and IgG anti-β2GPI-oxLDL by previously described immunoassays [2, 3], and PAF-AH by an established method [4]. Lipid profiles were normal in all participants according to measurements done two to three months earlier than the present measurements.
Table 1

Demographics and clinical features of the study populations

 

CTR

IT

PAPS

Participants (no.)

23

17

27

Female/male

13/7

11/6

18/9

Age (range)

42 (19–55)

40 (30–58)

38 (27–53)

Lupus anticoagulant

0

0

28

IgGaCL (GPL)

3 (1.5–6.0)

3.2 (1.4–6.8)

122 (24–573)

IgGβ2GPI (IU)

1 (0.78–3.4)

2 (0.8–4.8)

183 (31–226)

β2GPI-oxLDL (IU)

1.6 (1.0–9.0)

1.6 (0.5–6.5)

1.4 (0.8–1.8)

PAF-AH (nmol/ml/min)

46 (22–88)

43 (30–79)

39 (1.8–80)a

FVL

0

12

2

PT 20210

1

2

1

PC deficiency

0

3

0

IS

0

2

7

MI

0

0

1

DVT

0

11

14

PE

0

4

5

Smoking

2

2

4

Diabetes

0

0

0

Obesity

0

0

0

Aspirin (75 mg)

0

3

1

Warfarin

0

14

26

All numerical data expressed as median and range. p = 0.03 by Kruskal–Wallis ANOVA

CTR controls, IT inherited thrombophilia, PAPS primary antiphospholipid syndrome, FVL factor V Leiden, PT prothrombin 20210, PC protein C, IS ischaemic stroke, MI myocardial infarction, DVT deep vein thrombosis, PE pulmonary embolism

a p = 0.03

Table 1 shows the results: IgG aPL were elevated by definition in the PAPS group but median PAF-AH was lower in PAPS compared to the other groups (p = 0.03); PAF-AH correlated (Spearman rank) positively to β2GPI-oxLDL in the CTR (r = 0.49, p = 0.01) and in the IT (r = 0.56, p = 0.02) groups but negatively in the PAPS group (r = − 0.4, p = 0.03). In the latter group, free radical over-generation [5] may inhibit PAF-AH activity [6] perpetuating the effect of PAF that adds to the agonists favouring platelet activation alongside isoprostane [5], thromboxane [7] and thrombin [8]. Our data on low PAF-AH in established PAPS contrast with those of Fabris et al. [1] who do not provide the aPL titres of their screened population and fail to divide participants according to the vascular or obstetric manifestations of APS limiting the interpretation of their data. Our PAPS patients with arterial thrombosis showed a slightly lower PAF-AH than patients with venous thrombosis (33 ± 36 vs 38 ± 61 nmol/ml/min, non significant). In keeping with Fabris [1], we agree that larger studies with clearly defined subsets of patients are required to have a clearer picture on the thrombotic and/or atherogenic role of PAF-AH [9] in PAPS.

Notes

Compliance with ethical standards

Conflict of interest

None of the authors declare any conflict of interest.

References

  1. 1.
    Fabris M, Cifù A, Pistis C, Siega-Ducaton M, Fontana DE, Giacomello R, Tonutti E, Curcio F (2017) Exploring the plasmatic platelet-activating factor acetylhydrolase activity in patients with anti-phospholipid antibodies. Auto Immun Highlights 8:5CrossRefGoogle Scholar
  2. 2.
    Kobayashi K, Kishi M, Atsumi T et al (2003) Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716–726CrossRefGoogle Scholar
  3. 3.
    Liu Q, Kobayashi K, Furukawa J et al (2002) Omega-carboxyl variants of 7 ketocholesteryl esters are ligands for beta-(2)-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 43:1486–1495CrossRefGoogle Scholar
  4. 4.
    Tselepis AD, Karabina SA, Stengel D, Piedagnel R, Chapman MJ, Ninio E (2001) N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 42:1645–1654PubMedGoogle Scholar
  5. 5.
    Ames PRJ, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE (1998) Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost 79:447–449CrossRefGoogle Scholar
  6. 6.
    Ambrosio G, Oriente A, Napoli C et al (1994) Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet activating factor. J Clin Invest 93:2408–2416CrossRefGoogle Scholar
  7. 7.
    Ames PRJ, Tommasino C, Alves J, Morrow JD, Iannaccone L, Fossati G, Caruso S, Caccavo F, Brancaccio V (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9:688–695CrossRefGoogle Scholar
  8. 8.
    Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V (1996) Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies–a crucial role for acquired free protein S deficiency. Thromb Haemost 76:190–194CrossRefGoogle Scholar
  9. 9.
    Tsimikas S, Tsironis LD, Tselepis AD (2007) New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 27:2094–2099CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Paul R. J. Ames
    • 1
    Email author
  • Luis L. Lopez
    • 2
  • Mira Merashli
    • 3
  • Eiji Matsuura
    • 4
  1. 1.CEDOC, NOVA Medical School, Faculdade de Ciências MédicasUniversidade NOVA de LisboaLisbonPortugal
  2. 2.Corgenix, Inc. Medical DepartmentBroomfieldUSA
  3. 3.Department of RheumatologyAmerican University of BeirutBeirutLebanon
  4. 4.Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Neutron Therapy Research Center and Collaborative Research Center for OMICOkayama UniversityOkayamaJapan

Personalised recommendations